A publication by scientists of the Anticancer Fund

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

Marc-Eric Halatsch, Richard E. Kast, Georg Karpel-Massler, Benjamin Mayer, Oliver Zolk, Bernd Schmitz, Angelika Scheuerle, Ludwig Maier, Lars Bullinger, Regine Mayer-Steinacker, Carl Schmidt, Katharina Zeiler, Ziad Elshaer, Patricia Panther, Birgit Schmelzle, Anke Hallmen, Annika Dwucet, Markus D. Siegelin, Mike-Andrew Westhoff, Kristine Beckers, Gauthier Bouche, and Tim Heiland. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neuro-Oncology Advances, 3(1), 1–11, 2021, doi.org/10.1093/noajnl/vdab075
A publication by scientists of the Anticancer Fund

Discovery and 3D imaging of a novel ΔNp63- expressing basal cell type in human pancreatic ducts with implications in disease

PUBLICATION

Sandrina Martens, Katarina Coolens, Mathias Van Bulck, Tatjana Arsenijevic, Joan Casamitjana, Angel Fernandez Ruiz, Abdessamad El Kaoutari, Jaime Martinez de Villareal, Hediel Madhloum, Farzad Esni, Yves Heremans, Gunter Leuckx, Harry Heimberg, Luc Bouwens, Patrick Jacquemin, Diedert Luc De Paep, Peter in't Veld, Nicky D'Haene, Christelle Bouchart, Nelson Dusetti, Jean-Luc Van Laethem, Wim Waelput, Pierre Lefesvre, Francisco X Real, Meritxell Rovira, Ilse Rooman. Discovery and 3D imaging of a novel ΔNp63-expressing basal cell type in human pancreatic ducts with implications in disease. Gut 2021;0:1-13. doi: 10.1136/gutjnl-2020-322874

A publication by scientists of the Anticancer Fund

Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway

Nathalie C Støer, Gauthier Bouche, Pan Pantziarka, Erica K Sloan, Bettina K Andreassen, Edoardo Botteri. Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. Acta Oncol., 2021 Aug 2;1-8. doi: 10.1080/0284186X.2021.1953136
WHO - Repurposing medicines is the underrated champion of sustainable innovation in oncology - Anticancer Fund (with frame).jpg.png

WHO endorses drug repurposing strategy of the Anticancer Fund

First patient for EORTC-trial in oligometastatic rare cancers 

A publication by scientists of the Anticancer Fund

Trends in International Cancer Research Investment 2006-2018

Rachel Abudu, BS, MPH; Gauthier Bouche, MPH, MD; Karima Bourougaa, PhD; Lynne Davies, PhD; Kalina Duncan, BS, MPH; Carla Estaquio, PhD; Anna Diaz Font, PhD; Marc S. Hurlbert, PhD; Paul Jackson, PhD; Linda Kroeskop-Bossenbroek, PhD; Ian Lewis, PhD; Giota Mitrou, PhD; Abdul Mutabbir, BSc; Christopher A. Pettigrew, PhD; Lynn Turner, PhD; Annemarie Weerman, PhD; and Kari Wojtanik, PhD. Trends in International Cancer Research Investment 2006-2018. JCO Global Oncology, 2021 Apr;7:602-610. doi: 10.1200/GO.20.00591

Honorary association for Gauthier Bouche with University College London

Second step in trial for children with solid cancers